Stryker reports second quarter 2026 operating results
Stryker posted Q2 net sales of $6.6 billion, up 9.4% year-over-year, with organic growth of 9.0% driven by increased unit volume across both MedSurg and Orthopaedics segments. Adjusted EPS rose 17.9% to $3.69, reflecting a 170 basis point expansion in adjusted operating margin to 27.4%, aided partially by a one-time $158 million reversal of 2025 tariffs.
Key figures
- Eps
- 3.69
- Revenue
- 6589000000
- Guidance
- FY26 organic sales growth 8.3% to 9.3%; Adjusted EPS $14.95 to $15.10
- Revenue Yoy
- 9.4%
- Reported eps
- 3.3
- Organic sales growth
- 9.0%
- Adjusted operating income margin
- 27.4%
- Reported operating income margin
- 25.2%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.